In contrast, CED significantly enhanced ADC delivery to tumor and peri-tumoral regions and extended survival. In a pilot study in GBM6 with n=3 mice per group, a single CED infusion of 0.002mg ABBV-321 resulted in extended survival beyond 365 days for two mice, while other doses and ...
Samatatug Zovodotin | XB002 | ICON-2 Tissue Factor ADC Samrotamab vedotin | ABBV-085 | PR-1498487-MMAE SAR 566658 (SAR566658) SAR428926 Satoreotide tetraxetan Satumomab Penditide | OncoScint® CR/OV SC-006 SC16LD6.5 Serclutamab Talirine | ABBV-321 ...
1,321 0.75 Litigation matters 692 543 0.31 Other 30 19 0.01 As adjusted (non-GAAP) $ 6,357 $ 5,327 $ 3.00 a Represents net earnings attributable to AbbVie Inc. Acquisition and integration costs primarily reflect costs related to the Cerevel Therapeutics acquisition. Litigation matters primarily...
此外,艾伯维还有多个ADC被叫停,如ABBV-154(靶向TNFα,治疗风湿性多肌痛、克罗恩病、类风湿性关节炎等)、CX-2029(靶向CD71,治疗鳞状食管癌、鳞状NSCLC、头颈部鳞状细胞癌等)、ABBV-3373(靶向TNFα)、ABBV-414(靶向EGFR)、ABBV-221(靶向EGFR,治疗实体瘤)、ABBV-321(靶向EGFR,治疗类风湿性关节炎等)、ABBV-011(靶...